WR1065 is reported to target p53 by (i) enhancing p53 activity through prevention of its proteasomal degradation, (ii) increasing nuclear p53 protein levels in both normal and tumor cells, and (iii) activating a subset of mutant p53 proteins by restoring their active conformations (34–36). The gene discussed is TP53; the disease is neoplasm.